TMEM30A: A Potential Drug Target and Biomarker (G55754)

Target Name: TMEM30A

NCBI ID: G55754

TMEM30A

TMEM30A: A Potential Drug Target and Biomarker

TMEM30A (CDC50A), also known as CD28, is a protein that is expressed in various tissues throughout the body, including the skin, lungs, heart, and gastrointestinal tract. It is a member of the T-cell receptor (TCR) family, which is a protein that is responsible for cell-mediated communication between cells.

TMEM30A is a 28-kDa protein that is expressed in various tissues throughout the body, including the skin, lungs, heart, and gastrointestinal tract. It is a member of the T-cell receptor (TCR) family, which is a protein that is responsible for cell-mediated communication between cells. TMEM30A is a key regulator of T-cell development and function, and it has been implicated in a number of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

One of the most promising aspects of TMEM30A is its potential as a drug target. TMEM30A has been shown to play a role in a number of cellular processes, including T-cell development, activation, and regulation of T-cell proliferation. It has also been shown to be involved in the regulation of immune cell function, inflammation, and fibrosis. As a result, TMEM30A has been identified as a potential drug target for a number of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

In addition to its potential as a drug target, TMEM30A has also been shown to have potential as a biomarker. TMEM30A has been shown to be expressed in a number of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. As a result, TMEM30A has been used as a potential biomarker for a number of these diseases. For example, studies have shown that TMEM30A levels are elevated in the blood of patients with cancer, and that they are decreased in the blood of patients with autoimmune diseases.

TMEM30A is also a potential target for cancer because it has been shown to promote the growth and survival of cancer cells. For example, studies have shown that TMEM30A can inhibit the growth of cancer cells in a number of ways, including by inhibiting the activity of the T-cell receptor (TCR), which is responsible for cell-mediated communication between cells.

In addition to its potential as a drug target and biomarker, TMEM30A is also of interest as a potential therapeutic approach for a number of diseases. For example, studies have shown that TMEM30A can be downregulated in a number of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. As a result, TMEM30A has been shown to have potential as a therapeutic approach for these diseases.

In conclusion, TMEM30A is a protein that is expressed in various tissues throughout the body, including the skin, lungs, heart, and gastrointestinal tract. It is a member of the T-cell receptor (TCR) family, and it has been shown to play a role in a number of cellular processes, including T-cell development, activation, and regulation of T-cell proliferation. As a result, TMEM30A has been identified as a potential drug target and biomarker for a number of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. Further research is needed to fully understand the role of TMEM30A in these diseases and to develop effective therapies.

Protein Name: Transmembrane Protein 30A

Functions: Accessory component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of lipid signaling molecules. The beta subunit may assist in binding of the phospholipid substrate. Required for the proper folding, assembly and ER to Golgi exit of the ATP8A2:TMEM30A flippase complex. ATP8A2:TMEM30A may be involved in regulation of neurite outgrowth, and, reconstituted to liposomes, predomiminantly transports phosphatidylserine (PS) and to a lesser extent phosphatidylethanolamine (PE). The ATP8A1:TMEM30A flippase complex seems to play a role in regulation of cell migration probably involving flippase-mediated translocation of phosphatidylethanolamine (PE) at the plasma membrane. Required for the formation of the ATP8A2, ATP8B1 and ATP8B2 P-type ATPAse intermediate phosphoenzymes. Involved in uptake of platelet-activating factor (PAF), synthetic drug alkylphospholipid edelfosine, and, probably in association with ATP8B1, of perifosine. Also mediates the export of alpha subunits ATP8A1, ATP8B1, ATP8B2, ATP8B4, ATP10A, ATP10B, ATP10D, ATP11A, ATP11B and ATP11C from the ER to other membrane localizations

The "TMEM30A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM30A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets